NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2021-03, Vol.39 (7), p.797-806
Hauptverfasser:	Weiss, Brian D, Wolters, Pamela L, Plotkin, Scott R, Widemann, Brigitte C, Tonsgard, James H, Blakeley, Jaishri, Allen, Jeffrey C, Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J, Goldman, Stewart, Vinks, Alexander A, Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T, Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Benzamides - adverse effects Benzamides - pharmacokinetics Benzamides - therapeutic use Diphenylamine - adverse effects Diphenylamine - analogs & derivatives Diphenylamine - pharmacokinetics Diphenylamine - therapeutic use Female Humans Magnetic Resonance Imaging Male Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - metabolism Neurofibroma, Plexiform - diagnostic imaging Neurofibroma, Plexiform - drug therapy Neurofibroma, Plexiform - enzymology Neurofibromatosis 1 - diagnostic imaging Neurofibromatosis 1 - drug therapy Neurofibromatosis 1 - enzymology Original Reports Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Time Factors Treatment Outcome United States Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!